Seattle Genetics and CuraGen Announce Antibody-Drug Conjugate -- ADC -- Agreement.BOTHELL, Wash. & NEW HAVEN New Haven, city (1990 pop. 130,474), New Haven co., S Conn., a port of entry where the Quinnipiac and other small rivers enter Long Island Sound; inc. 1784. Firearms and ammunition, clocks and watches, tools, rubber and paper products, and textiles are among the many , Conn. -- Seattle Genetics' ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. Technology to be Used with CuraGen's Proprietary Antibodies Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) and CuraGen Corporation (Nasdaq:CRGN) announced today that CuraGen has licensed Seattle Genetics' proprietary ADC technology for use with CuraGen's proprietary antibodies for the treatment of cancer. CuraGen will pay an upfront fee of $2.0 million for access to the ADC technology for one of CuraGen's proprietary antibody programs. CuraGen also has an option to access Seattle Genetics' ADC technology for a second CuraGen proprietary antibody program in exchange for payment of an additional fee. "Our industry-leading ADC technology can be widely employed to increase the therapeutic potential of monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). through stable attachment to cell-killing drug payloads," stated Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We believe ADCs will play a significant role in the future of antibody-based treatments for patients with cancer and other diseases. We look forward to collaborating with CuraGen on ADCs directed to disease targets identified through CuraGen's proprietary genomics platform." "We are pleased to be working with Seattle Genetics as we have multiple proprietary antibodies that specifically target tumor tumor: see neoplasm. cells that we are advancing to clinical development in 2005 and beyond, and the use of Seattle Genetics' industry-leading ADC technology greatly enhances our ability to create more potent therapies," stated Jonathan M. Rothberg The creator of this article, or someone who has substantially contributed to it, may have a conflict of interest regarding its subject matter. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. , Ph.D., CuraGen's Chief Executive Officer, President and Chairman. "As we continue to advance CG53135 and PXD PXD Powder X-ray Diffraction PXD Post Exercise Discussion PXD Physical Device Driver PXD Pixel Data 101 through clinical development and initiate clinical trials for our first fully human monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing , CR002, we are building important clinical momentum which will set the stage for additional drugs coming from our unique ability to leverage genomics and synergistic technologies." Under the terms of the multi-year agreement, Seattle Genetics may receive up to $28 million in milestone payments assuming successful development of two antibody therapeutics employing ADC technology and will receive royalties on net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of resulting products. CuraGen is responsible for research, product development, manufacturing and commercialization of all products under the collaboration. CuraGen will pay maintenance and material supply fees as well as research support payments for any assistance provided by Seattle Genetics in developing ADC products. CuraGen has taken a systematic approach to identify and select targets from the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. for drug development. Through a broad collaboration with Abgenix, CuraGen has today several proprietary antibodies in animal validation for oncology and inflammatory disease Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; . The collaboration between CuraGen and Seattle Genetics will enable CuraGen to develop therapies that specifically target cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer using ADC technology with its proprietary antibodies. CuraGen expects to announce in 2004 additional candidates for clinical development in 2005 and beyond taken from its pipeline of protein, antibody and small molecule programs currently in animal validation. Seattle Genetics' ADC technology utilizes the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. This ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload (1) Refers to the "actual data" in a packet or file minus all headers attached for transport and minus all descriptive meta-data. In a network packet, headers are appended to the payload for transport and then discarded at their destination. under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy. ADCs can increase the therapeutic potential of the many antibodies with targeting ability but limited or no inherent cell-killing activity. About Seattle Genetics Seattle Genetics discovers and develops monoclonal antibody-based therapeutics to treat cancer and other human diseases. The company has built a diverse portfolio of product candidates targeted to many types of cancer, including three being tested in multiple ongoing clinical trials, SGN-30, SGN-15 and SGN-40, and three in preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development, SGN-35, SGN-75 and SGN-17/19. The product candidates encompass three platform technologies: genetically engineered genetically engineered adjective Recombinant, see there monoclonal antibodies, antibody-drug conjugates (ADCs) and antibody-directed enzyme prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. therapy (ADEPT). Seattle Genetics has developed leading ADC technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company currently has license agreements for its ADC technology with Genentech, Celltech Group and Protein Design Labs and for its ADEPT technology with Genencor International. More information about Seattle Genetics can be found at www.seattlegenetics.com. About CuraGen CuraGen Corporation (Nasdaq:CRGN) is a genomics-based pharmaceutical company dedicated to improving the lives of patients by developing a pipeline of novel protein, antibody, and small molecule therapeutics in the areas of oncology, inflammation, and obesity and diabetes. CuraGen's therapeutics are based on targets from the human genome that are believed to play a role in important mechanisms underlying disease, including cell proliferation proliferation /pro·lif·er·a·tion/ (pro-lif?er-a´shun) the reproduction or multiplication of similar forms, especially of cells.prolif´erativeprolif´erous pro·lif·er·a·tion n. , anti-angiogenesis and peripheral metabolism. CuraGen has established broad development alliances with Abgenix and Bayer, and its experienced preclinical and clinical teams are rapidly advancing the Company's pipeline of products for unmet medical needs. CuraGen's expertise in systems biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. , genomics and bioinformatics is now being used to prioritize therapeutic candidates with the highest chance of reaching the market and to help predict efficacy and safety in clinical trials. CuraGen's technology and expertise has been used in partnerships with more than a dozen leading biotechnology and pharmaceutical companies, including Bayer, Biogen, Genentech, GlaxoSmithKline, Hoffmann-La Roche and Pfizer. The Company is headquartered in New Haven, CT, and additional information is available at http://www.curagen.com. For Seattle Genetics: Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Specifically, the statements regarding the potential benefits of the combination of Seattle Genetics' and CuraGen's technologies and payments Seattle Genetics may receive from CuraGen as part of the collaboration are forward-looking and actual results may differ materially from these statements for various reasons. Factors that may cause such a difference include difficulties in implementing the combined technologies of Seattle Genetics and its partners, risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early-stage development and failure by Seattle Genetics to secure collaborators or failure of those collaborators to perform their contractual obligations. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For CuraGen: This press release may contain forward-looking statements, including statements about the potential benefits of the combination of Seattle Genetics' and our technologies, our expectation to advance multiple proprietary antibodies that specifically target tumor cells into clinical development in 2005 and beyond, our ability to use Seattle Genetics' industry-leading ADC technology to create more potent therapies, our plan to develop additional drugs from our unique ability to leverage genomics and synergistic technologies, and our expectation to announce in 2004 additional candidates for clinical development in 2005 and beyond taken from our pipeline of protein, antibody and small molecule programs currently in animal validation. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. CuraGen cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: CuraGen's stage of development as a genomics-based pharmaceutical company, uncertainties of clinical trials, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc commercialization rights. Please refer to our Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the period ended March 31, 2004, for a description of these risks. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion